Creative Medical Technology Holdings, Inc. Common Stock
CELZ
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
Last trade$0.49
Day change-$0.0301 (-5.79%)
Day range$0.453 – $0.546
Volume81,314
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.95M
Price / earnings
—
Price / book
0.57×
Price / sales
1,316.91×
EV / sales
-965×
EV / EBITDA
0.38×
Profitability
Earnings per share
-$0.98
Return on assets
-102.69%
Return on equity
-107.48%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
23.66×
Quick ratio
23.66×
Cash ratio
23.35×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CELZ, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$3K
$0
$0
$3K
$3K
Cost of revenue
$0
$0
$0
$994
$0
$0
$1.2K
$1.2K
Gross profit
$0
$0
$0
$2.01K
$0
$0
$1.8K
$1.8K
Selling, general and administrative
$1.11M
$1.08M
$888.64K
$1.37M
$776.82K
$731.52K
$888.4K
$1.39M
Research and development
$1.6M
$459.2K
$541.66K
$550.08K
$465.15K
$501.26K
$743.3K
$471.84K
Total operating expenses
$2.73M
$1.56M
$1.46M
$1.95M
$1.27M
$1.26M
$1.66M
$1.89M
Operating income
-$2.73M
-$1.56M
-$1.46M
-$1.95M
-$1.27M
-$1.26M
-$1.66M
-$1.89M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$2.66M
-$1.51M
-$1.4M
-$1.89M
-$1.24M
-$1.23M
-$1.64M
-$1.85M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.66M
-$1.51M
-$1.4M
-$1.89M
-$1.24M
-$1.23M
-$1.64M
-$1.85M
Net income attributable to common shareholders
-$2.67M
-$1.51M
-$1.41M
-$1.89M
-$1.24M
-$1.23M
-$1.64M
-$1.85M
EBITDA
-$2.71M
-$1.54M
-$1.43M
-$1.91M
-$1.24M
-$1.23M
-$1.63M
-$1.86M
Basic earnings per share
-$0.40
-$0.41
-$0.38
-$0.79
-$0.48
-$0.48
-$0.83
-$1.09
Diluted earnings per share
-$0.40
-$0.41
-$0.38
-$0.79
-$0.48
-$0.48
-$0.83
-$1.09
Recent news
Company coverage with links to the original publishers.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced agreements to exercise existing warrants for $4.5 million in gross proceeds. The company will issue new unregistered warrants to purchase up to 5.58 million shares at $1.60 per share, pending shareholder approval. Net proceeds will be used for working capital and general corporate purposes.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced the advancement of Project PHOENIX into a nationwide virtual data collection phase targeting at least 1,000 U.S. veterans exposed to burn pits and toxic hazards. The AI-driven platform leverages mobile-app technology and field-capable logistics to collect exposure history, health data, and multi-omics profiling. The company is developing the CELZ-Biodefense Toxic Exposure Atlas to identify biomarkers and therapeutic targets while maintaining capital efficiency through existing infrastructure.
Creative Medical Technology Holdings announced promising mid-term follow-up data from its StemSpine® pilot study, which demonstrated a substantial reduction in opioid dependency and significant improvements in pain levels and functional mobility for chronic lower back pain patients.
PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin.
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results.
HighPeak Energy posted GAAP earnings of 66 cents per share, versus market estimates of 65 cents per share. The company’s quarterly sales came in at $301.153 million versus expectations of $339.525 million.
HighPeak Energy shares declined 15.3% to $13.49 on Thursday.
Here are some other stocks moving in today's mid-day session.
Gainers
Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares jumped 404% to $11.65 after the company announced the launch of Lytus Cloud.
CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) gained 167% to $6.81. CERo Therapeutics announced the publication in clinical cancer research a paper titled "Therapeutic Targeting of TIM-4-L With Engineered T CellsFor Acute Myeloid Leukemia."
Brera Holdings PLC (NASDAQ: BREA) shares climbed 97.5% to $2.0150 after the company announced that its Executive Chairman, Daniel McClory, acquired a majority stake in the company.
Grom Social Enterprises, Inc. (NASDAQ: GROM) gained 88.3% to $1.45. The company announced that it entered into a non-binding letter of intent to acquire Arctic7.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 43% to $6.83. Creative Medical Technology announces FDA authorization for groundbreaking Type 1 diabetes prevention therapy under expanded access.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) gained 40.5% to $8.35 after the company received FDA Breakthrough Therapy Designation for its MM120 program in generalized anxiety disorder. The company also announced 12-week durability data from its Phase 2B study of MM120.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) jumped 34.2% to $2.1601 after the company announced that its subsidiary BioStrand developed a Foundation AI Model that uses Large Language Models Stacking and HYFT Technology.
Beneficient (NASDAQ: BENF) shares rose 28.7% to $0.1287. Beneficient agreed to the financing of liquidity transactions for three separate funds managed by ff Venture Capital.
MoneyLion Inc. (NYSE: ML) gained 28.3% to $67.43 ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.